Sinil Pharmaceutical Co. Ltd (012790) — Cash Flow Reinvestment Rate
Sinil Pharmaceutical Co. Ltd (012790) has a Cash Flow Reinvestment Rate of 0.16x as of September 2025, reinvesting ₩426.30 Million (capex ₩213.15 Million plus investments ₩-213.15 Million) from operating cash flow of ₩2.62 Billion. See how much free cash does Sinil Pharmaceutical Co. Ltd generate to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Sinil Pharmaceutical Co. Ltd Cash Flow Reinvestment Rate (2014–2024)
Historical reinvestment intensity for Sinil Pharmaceutical Co. Ltd across 11 annual periods. For the full cash flow conversion analysis, see 012790 cash flow metrics.
Annual Cash Flow Reinvestment Rate for Sinil Pharmaceutical Co. Ltd (2014–2024)
Year-by-year capital reinvestment analysis for Sinil Pharmaceutical Co. Ltd. See financial flexibility index of Sinil Pharmaceutical Co. Ltd to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.41x | ₩31.94 Billion | ₩22.69 Billion | ₩8.47 Billion | ▼ -12.0% |
| 2023 | 1.60x | ₩24.24 Billion | ₩15.15 Billion | ₩12.92 Billion | ▼ -9.6% |
| 2022 | 1.77x | ₩24.21 Billion | ₩13.69 Billion | ₩9.33 Billion | ▲ +193.3% |
| 2021 | 0.60x | ₩6.73 Billion | ₩11.16 Billion | ₩3.63 Billion | ▼ -25.7% |
| 2020 | 0.81x | ₩8.98 Billion | ₩11.06 Billion | ₩8.80 Billion | ▲ +1.1% |
| 2019 | 0.80x | ₩9.88 Billion | ₩12.31 Billion | ₩9.73 Billion | ▼ -19.3% |
| 2018 | 1.00x | ₩9.15 Billion | ₩9.19 Billion | ₩8.33 Billion | ▼ -30.2% |
| 2017 | 1.42x | ₩12.36 Billion | ₩8.67 Billion | ₩9.38 Billion | ▲ +315.4% |
| 2016 | 0.34x | ₩4.15 Billion | ₩12.09 Billion | ₩2.57 Billion | ▼ -48.2% |
| 2015 | 0.66x | ₩6.34 Billion | ₩9.56 Billion | ₩5.80 Billion | ▼ -19.7% |
| 2014 | 0.83x | ₩7.70 Billion | ₩9.33 Billion | ₩2.24 Billion | — |